**EAACI position paper: Comparing insect hypersensitivity induced by bite, sting, inhalation or ingestion in human beings and animals**

I. Pali-Schöll1, S. Blank2, K. Verhoeckx3,4, R.S. Mueller5, J. Janda6, E. Marti7,A.A. Seida8, C. Rhyner9, D.J. DeBoer10, E. Jensen-Jarolim1,11

1 Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University of Vienna and University of Vienna, Vienna, Austria

2 Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Member of the German Center of Lung Research (DZL), Munich, Germany

3 Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.

4 TNO, Zeist, the Netherlands.

5 Centre for Clinical Veterinary Medicine, Ludwig Maximilian University Munich, Munich, Germany

6 Faculty of Science, Charles University, Prague, Czech Republic

7 Department of Clinical Research and Veterinary Public Health, Vetsuisse Faculty, University of Berne, Berne, Switzerland

8 Department of Microbiology and Immunology, Faculty of Veterinary Medicine, Cairo University, Egypt

9 Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland

10 School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin USA

11 Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria

**Correspondence:**

PD DDr. Isabella Pali-Schöll; The Interuniversity Messerli Research Institute; University of Veterinary Medicine Vienna, Medical University Vienna, University Vienna; Veterinärplatz 1, 1210 Vienna, Austria. E-mail: [isabella.pali@vetmeduni.ac.at](mailto:isabella.pali@vetmeduni.ac.at); [isabella.pali@meduniwien.ac.at](mailto:isabella.pali@meduniwien.ac.at)

**Short title:** Comparing insect hypersensitivity in human beings and animals

**Acknowledgment**

The Working Group for Comparative and Veterinary Allergology was financed by the European Academy for Allergy and Clinical Immunology (EAACI). The authors would like to thank EAACI for its financial support in the development of this Working Group report. Work during this review was supported by the Austrian Science Fund (FWF) (grant SFB F4606-B28 to EJJ) and by the Swiss National Science Foundation (grant no. 310030-160196/1 to EM).

**Key words:** comparative, insect venom allergy, insect bite hypersensitivity, insect food allergy, allergenic molecules in insects

**Abbreviations:**

BAT, basophil activation test

CCD, cross-reactive carbohydrate determinant

CRD, component-resolved diagnosis

DBPCFC, double-blind placebo-controlled food challenge

FBH, flea bite hypersensitivity

HDM, house dust mite

IBH, insect bite hypersensitivity

IGR, insect growth regulator

LLR, large local reaction

MBH, mosquito bite hypersensitivity

RAST, radioallergosorbent test

VIT, venom immunotherapy

**Word count**: 5100

**Abstract**

Adverse reactions to insects occur in both human and veterinary patients. Systematic comparison may lead to improved recommendations for prevention and treatment in all species. In this position paper, we summarize the current knowledge on insect allergy induced via stings, bites, inhalation or ingestion, and compare reactions in companion animals to those in people. With few exceptions, the situation in human insect allergy is better documented than in animals. We focus on a review of recent literature, and give overviews of the epidemiology and clinical signs. We discuss allergen sources and allergenic molecules to the extent described, and aspects of diagnosis, prophylaxis, management and therapy.

**1. Pathogenesis of insect allergy**

The most important risk factor for insect allergies of any kind in people as well as in animals is exposure, either by sting, bite, respiratory or dietary encounter. According to the Centers for Disease Control and Prevention, deaths due to Hymenoptera hypersensitivity make up 29.7% of nonhuman species-related fatalities in people in the US ([1](#_ENREF_1)). An atopic phenotype and defective skin barrier seem to correlate with more severe local and systemic reactions ([2](#_ENREF_2)), which is pronounced by comorbidities at older age ([3](#_ENREF_3)). While robust data regarding atopy exist in people, the situation in pet- and farm animals has been investigated only recently. Dog breeds with a high prevalence of atopic skin disorders include the West Highland white terrier, Boxer, English bulldog, Dalmatian and French bulldog ([4](#_ENREF_4)). In a Turkish human cohort, 33% of Hymenoptera reactive patients had atopic diseases ([5](#_ENREF_5)), in a Mexican study on beekeepers with atopic family history it was 3.9% (CI 1.7-9.2) ([6](#_ENREF_6)). More recently it was proposed that IgE to Hymenoptera venom could have a beneficial role ([7](#_ENREF_7)), but atopic patients with Hymenoptera sensitivity also form IgE against CCDs ([8](#_ENREF_8)). In small animals anaphylaxis due to Hymenoptera stings is a known ([9](#_ENREF_9)), but rare event ([10](#_ENREF_10)).

**2. Hymenoptera sting allergies**

**2.1. Hymenoptera sting allergy in human beings**

***2.1.1. Epidemiology***

The prevalence of systemic bee and wasp sting reactions ranges between 0.3%-7.5% in adults and up to 3.4% in children ([11](#_ENREF_11), [12](#_ENREF_12)). Large local reactions (LLRs) occur in 2.4%-26.4% of the general population ([13](#_ENREF_13)). The estimated number of deaths from sting reactions ranges from 0.03-0.45/million inhabitants annually ([14](#_ENREF_14)). In adults, 48.2% (in children 20.2%) of cases of severe anaphylaxis are caused by insect stings ([15](#_ENREF_15)). The onset of venom allergy can be at any age ([16](#_ENREF_16)) without significant differences in the frequency in non-atopic and atopic individuals ([17](#_ENREF_17)).

***2.1.2. Clinical signs***

In allergic individuals, just a single sting can lead to severe or fatal reactions. Systemic reactions can be mild (urticaria or angioedema), moderate (dyspnoea, gastrointestinal symptoms, dizziness) or severe (unconsciousness, shock, respiratory or cardiac arrest) ([18](#_ENREF_18)). The severity of one sting reaction does not necessarily correlate with the severity of subsequent reactions ([16](#_ENREF_16)). LLRs at the site of the sting, which are thought to be IgE-mediated or cell-dependent, are characterised by a swelling (diameter exceeding 10 cm) that lasts for more than 24 h ([19](#_ENREF_19)).

***2.1.3. Allergen sources and allergen molecules***

In northern and central Europe the most common elicitors of venom allergy are honeybees (*Apis mellifera*) and yellow jackets (*Vespula spp.*), and in southern Europe and America, also paper wasps (*Polistes spp.*). Stinging ants (jumper ant in Australia, needle ant in Asia, fire ant in America) may elicit venom allergy. Increasing knowledge of venom composition on a molecular level (**Table 1)** has led to considerable improvements in diagnostic and therapeutic options ([20](#_ENREF_20)). Venom allergens can be either species-specific or homologous in different species, leading to cross-reactivity.

***2.1.4. Diagnosis***

Diagnosis of venom allergy comprises clinical history, skin testing and/or the detection of venom-specific serum IgE antibodies. Cellular tests like the BAT can be used in unclear cases. When the patient is not able to identify the culprit insect, diagnosis can be challenging despite convincing clinical history ([20](#_ENREF_20)). Positive serologic results with limited or no clinical relevance can be caused by: i) IgE directed against epitopes of homologous allergens, ii) IgE directed against CCDs, and iii) asymptomatic sensitisation. Negative results may be caused by the underrepresentation of particular allergens in venom extracts or very low specific IgE. The development of CRD has improved the sensitivity of IgE detection, and enables discrimination between primary sensitisation and cross-reactivity, particularly in patients with sensitisation to both honeybee and vespid venom ([20](#_ENREF_20)).

***2.1.5. Prophylaxis, management and therapy***

Although behavioural advice may lower risk, avoidance of a sting is hard to achieve. Patients with venom allergy should carry an emergency kit including an adrenaline/epinephrine autoinjector, H1-antagonist antihistamines and corticosteroids ([18](#_ENREF_18)). The only disease-modifying and curative treatment for Hymenoptera venom allergy, reducing the risk of subsequent reactions and improving the patients’ quality of life, is VIT ([18](#_ENREF_18)). VIT is reportedly effective in 77%-84% of patients treated with honeybee venom, in 91%-96% of patients receiving vespid venom and in 97%-98% of patients treated with ant venom ([18](#_ENREF_18)). VIT is recommended for adults and children developing systemic reactions exceeding generalised skin symptoms with sensitisation.

**2.2. Insect sting allergy in animals**

***2.2.1. Epidemiology***

In animals, the three medically important groups of stinging insects are the *Apoidea* (bees), *Vespidae* (wasps, hornets, yellow jackets) and the *Formicidae* (ants) ([9](#_ENREF_9), [21](#_ENREF_21)). The exact prevalence of allergies to stinging insects in pets is unknown. It is reported that some dog breeds, like bull terrier, boxers and Staffordshire terriers are more prone to severe reactions following insect stings ([22](#_ENREF_22)).

***2.2.2. Clinical signs***

Signs in allergic animals after Hymenoptera stings can vary from LLRs to life-threatening anaphylactic responses with urticaria, angioedema, gastrointestinal signs, low blood pressure and asthmatic symptoms, occurring within minutes after the sting. Less often, skin rashes and serum-sickness signs can occur after 3 days to weeks, due to immune complex mediated delayed-type hypersensitivity.

***2.2.3. Allergen sources and allergen molecules***

The same allergens that are important causes of human allergic reactions (listed in **Table 1**), also seem to be relevant in pets, though there is minimal literature support for this concept.

***2.2.4. Diagnosis***

Diagnosis is mainly based on the history, if a human observer was present, regarding the type of stinging insect and the time until appearance of symptoms. Skin tests, venom-specific IgE, histamine release assays, and provocation test with actual stings of presumed allergy-provoking insects are anecdotally indicated as possibilities in the literature ([9](#_ENREF_9)).

***2.2.5. Prophylaxis, management and therapy***

Prophylactic measures for companion animals include avoidance of flowering areas (bees) and limiting consumption of food leftovers (wasps), in addition to keeping all pet food, sweet drinks and garbage in thoroughly closed containers. Scented grooming products, which may attract insects, should not be used. First-line measures after insect stings include application of ice or cooling bags and antihistamines. If signs of anaphylaxis appear, rapid administration of epinephrine and intravenous fluids are necessary, after which antihistamines and corticosteroids may be necessary. A collar tag identifying the animal as being allergic could help save precious time in emergency cases.

**3. Insect bite hypersensitivity**

***3.1. Insect bite allergy in human beings***

***3.1.1. Epidemiology***

Bites of blood-sucking insects like mosquitos, horseflies, beetles, lice and fleas are important elicitors of allergy in people ([23](#_ENREF_23)). Increasing evidence also points towards a role of midges, ladybeetles, caterpillars, or stink bugs in eliciting adverse local reactions, asthma or anaphylaxis ([24](#_ENREF_24), [25](#_ENREF_25)). The prevalence of localized cutaneous reactions to mosquito bites is best documented, with IgE-mediated immediate- (75%) or delayed-type reactions (50%), and sometimes combined reactions, seen in the general population ([23](#_ENREF_23)). Generally, only large or atypical (ecchymotic or vesiculated) localized reactions, or systemic reactions are considered to be allergy ([26](#_ENREF_26)). Finnish studies indicate that 10% of the exposed population are allergic to mosquito bites ([27](#_ENREF_27)). Systemic reactions to the bites of haematophagous insects -mainly to horseflies ([28](#_ENREF_28)), mosquitos ([29](#_ENREF_29)) and kissing bugs ([30](#_ENREF_30))- are extremely rare, most likely due to the limited amount of allergens inoculated through the bite.

***3.1.2. Clinical signs***

In people, bites of haematophagous insects mainly elicit local cutaneous reactions (Fig. 1). Reactions are either immediate wheal-and-flare reactions, mediated by specific IgE antibodies, or allergen-specific T cell-driven delayed reactions, characterised by pruritic indurated papules ([31](#_ENREF_31)). LLRs or type II and III hypersensitivity reactions accompanied by blistering or Arthus-type reactions ([32](#_ENREF_32), [33](#_ENREF_33)) can also occur. Rare systemic reactions to insect bites include generalised urticaria, angioedema, bronchoconstriction and shock ([29-31](#_ENREF_29), [34](#_ENREF_34)).

***3.1.3. Allergen sources and allergen molecules***

All haematophagous insects inject saliva into their victims during bloodsucking. The saliva contains anticoagulants, vasodilators, antimicrobial peptides and digestive enzymes, many of which may act as allergens, but about which surprisingly little is known. The identified allergens are listed in **Table 2**.

***3.1.4. Diagnosis***

Clinical history is very important, as other options to diagnose haematophagous insect allergy are limited and unsatisfactory. Only non-standardised whole-body extracts (where relevant salivary allergens might be underrepresented) of a limited number of species like mosquito, horsefly or kissing bug are commercially available for skin testing or serologic diagnosis. Since sequences of many proteins in the saliva of haematophagous species are highly conserved, extensive cross-reactivity with other species may occur, with unknown clinical relevance.

***3.1.5. Prophylaxis, management and therapy***

In allergic individuals, prophylaxis against bites of the relevant species is most important and includes adequate clothing, mosquito nets, fly screens and use of repellents. In patients with strong allergic reactions to bites of haematophagous species, oral premedication with H1-antagonist antihistamines has proven effective in reducing symptoms, whereas topical administration of the same compounds is not effective ([35](#_ENREF_35)). Topical or systemic corticosteroids can be used to treat intense delayed reactions. Currently, no standardised allergen-specific immunotherapy against biting insects is available; recent experimental approaches showed variable outcomes ([36](#_ENREF_36), [37](#_ENREF_37)).

***3.2. Insect bite hypersensitivity in horses***

***3.2.1. Epidemiology***

In horses, IBH can be caused by blackflies, stable flies, hornflies, mosquitoes, deerflies, horseflies and (most importantly) the biting midge *Culicoides* spp. IBH from *Culicoides* hypersensitivity, also called “summer eczema” or “sweet itch”, is the most frequent allergic skin disease of horses, with a worldwide prevalence ranging from 3% in Great Britain to 60% in Queensland, Australia ([38](#_ENREF_38), [39](#_ENREF_39)). Disease onset is usually between 2 and 4 years of age, and all breeds of horses can be affected. The large variation in prevalence in different countries can be explained by genetic ([38](#_ENREF_38" \o "Schaffartzik, 2012 #3170), [39](#_ENREF_39" \o "Noli, 2014 #3174)) and environmental factors, as well as varying exposure to the midges. In Iceland, *Culicoides* spp. are absent, and IBH is thus not observed. However, following importation of adult Icelandic horses into *Culicoides*-rich environments in Europe or the USA, over 50% develop IBH within two years. In contrast, Icelandic breed horses born in Europe have a much lower prevalence of IBH of 7-8% ([38](#_ENREF_38), [39](#_ENREF_39)), similar to the prevalence in other breeds**.** Interestingly, the IBH incidence is much lower when the horses are imported at young age ([38](#_ENREF_38)), probably because regulatory T cells can be induced more easily in young horses ([40](#_ENREF_40)).

***3.2.2. Clinical features***

The major clinical sign associated with IBH is severe pruritus. The distribution of the lesions (Fig. 1) correlates with the preferential landing sites of the insects. Most commonly, the dorsal midline (mane, lateral neck, withers, and base of the tail) and sometimes also the ventral midline are affected: rarely, the face, ears and legs may be involved. In early stages, papular lesions are seen with tufting of hair, but secondary lesions due to self-trauma soon supersede, leading to broken and damaged hair, progressing to localised alopecia. Self-inflicted damage can cause erosions and excoriations, and secondary bacterial infections may occur ([39](#_ENREF_39)). Chronically affected animals show more extensive alopecia with lichenification of skin and scaling, developing into transverse ridges. Histology of IBH lesions is consistent with a hypersensitivity reaction with perivascular to diffuse infiltration of eosinophils and mononuclear cells. Increased numbers of tryptase-positive mast cells and IgE- as well as MHC-II-positive cells (likely Langerhans cells) have been found ([38](#_ENREF_38), [39](#_ENREF_39)). The epidermis is hyperplastic with hyperkeratosis. Various studies using intradermal testing, histamine or sulfidoleukotriene release assays, or passive transfer anaphylaxis have confirmed IgE-mediated type I hypersensitivity reactions in equine IBH ([38](#_ENREF_38)).

***3.2.3. Allergen sources and allergen molecules***

Twenty-two salivary gland allergen molecules derived from *Culicoides nubeculosus*, *sonorensis* and *obsoletus* have been characterised (**Table 3**). *Simulium* spp (blackflies) might also be involved, as IBH-affected horses react more frequently than non-affected controls to blackfly allergens, probably due to cross-reactivity between *Culicoides* and *Simulium* allergens, as demonstrated for the antigen 5-like protein ([38](#_ENREF_38)). *Simulium* spp occur in Iceland, and bite horses without inducing IBH, indicating that sensitisation to *Simulium* in IBH-affected horses is probably secondary to sensitisation to *Culicoides* allergens.

***3.2.4. Diagnosis***

Diagnosis of IBH is primarily based on history and clinical examination. In geographic areas where the occurrence of *Culicoides* is seasonal, the seasonality of the disease isa useful indication. Commercially available tests for allergen-specific IgE determination are unsatisfactory, because they use whole-body extracts of laboratory-bred *Culicoides* species that are rarely found in the environment of horses, resulting in low sensitivities and specificities ([38](#_ENREF_38)). A more reliable IgE serology should be possible using purified recombinant *Culicoides* allergens ([41](#_ENREF_41), [42](#_ENREF_42)). Intradermal tests with *Culicoides* whole-body extracts often result in positive reactions in healthy horses, although IBH-affected horses react significantly more frequently. Basophil activation tests with *Culicoides* extracts are useful to confirm IBH.

***3.2.5. Prophylaxis, management and therapy***

In IBH-affected horses, the use of blankets, repellents like permethrin, and stabling of horses at dawn and dusk (when midges are most active) are most important for prevention ([39](#_ENREF_39)). Glucocorticoids are the most effective treatment, but aggressive use may cause severe adverse effects in horses, such as gastrointestinal ulceration or laminitis. For AIT, placebo-controlled studies have so far failed to demonstrate efficacy ([38](#_ENREF_38), [39](#_ENREF_39)), probably due to the use of crude whole-body extract. The availability of pure recombinant allergens should improve AIT in the future. The potential of prophylactic immunization using intralymphatic immunization with recombinant allergens ([43](#_ENREF_43)) or with transgenic barley, expressing *Culicoides* allergens, is currently being explored ([44](#_ENREF_44)). Using an active vaccination against IL-5 resulted in significant improvement of symptoms in nearly 50% of the treated horses, thus being a promising treatment option ([45](#_ENREF_45)).

**3.3. Flea bite hypersensitivity in dogs and cats**

***3.3.1. General information and epidemiology***

FBH is the most common hypersensitivity in small animals and the cat flea *Ctenocephalides* *felis* is the most important ectoparasite of dogs and cats worldwide ([46](#_ENREF_46)). Fleas are obligate parasites, spend their lifetime on the host, feed at least once every 48 hours and lay up to 40 eggs per day. Those eggs drop off the host and after a few days hatch into larvae that live off debris, flea eggs and undigested blood in flea faeces before pupation in a protected microenvironment like floor crevices, or plant debris ([47](#_ENREF_47)). The flea within the pupa may survive for up to six months before it hatches and jumps onto the host.

***3.3.2. Clinical signs***

FBH is associated with pruritus and in the dog leads to papules, crusts, alopecia, hyperpigmentation and lichenification, affecting the caudal half of the body, predominantly the dorsal lumbosacral area, tail fold, the caudal and inner thighs and the abdomen (Fig. 1). In the cat, it is associated most commonly with miliary dermatitis, non-inflammatory alopecia, lesions of the eosinophilic granuloma complex, and head-and-neck pruritus ([48](#_ENREF_48)).

***3.3.3. Allergen sources and allergen molecules***

FBH develops to salivary antigens of 12-18 kDa and 40 kDa injected during feeding ([49](#_ENREF_49)). The first major allergen to be identified, relevant in up to 90% of flea-allergic dogs, was Cte f 1 ([50](#_ENREF_50)). Intradermal testing with Cte f 1 was positive in 6/15 dogs with FBH, while 14 of those dogs showed a positive reaction to whole flea saliva ([51](#_ENREF_51)).

***3.3.4. Diagnosis***

Diagnosis is based mainly on clinical signs and typical distribution. In most patients with FBH, fleas are neither numerous nor easily found, presumably due to vigorous self-grooming. In one study, 33% of fleas placed on cats were removed by grooming within 72 hours. The finding of dorsal lumbosacral pruritus is considered diagnostic of FBH until proven otherwise. Many dogs with FBH show positive reactions with intradermal or serum testing with flea extract, but healthy animals may also be positive ([48](#_ENREF_48), [51](#_ENREF_51)). Diagnosis is confirmed by a positive response to appropriate flea control in animals with corresponding clinical signs.

***3.3.5. Prophylaxis, management and therapy***

Increasing numbers of ectoparasiticides have been registered worldwide as efficacious flea control agents. They are delivered by sprays, topical spot-ons, collars and tablets, with oral ectoparasiticides acting faster than spot-ons ([47](#_ENREF_47)). Adulticides may be combined with IGRs like methoprene or pyriproxifen, which inhibit the pupation of larvae and development of adult fleas. Integrated flea control (use of a combination of adulticides and IGRs) is recommended to decrease the likelihood of fleas developing resistance against individual substances. All dogs and cats in the household must be treated regularly for optimal efficacy ([47](#_ENREF_47)). Toxicities can occur in cats, predominantly through the use canine products not registered for cats, such as permethrin. Therapeutic failure of flea control is mainly due to lack of owner compliance ([47](#_ENREF_47)).

**3.4. Mosquito bite hypersensitivity in cats**

***3.4.1. Epidemiology***

Feline MBH appears as an ulcerative and crusted dermatitis of the face, ears and paws in geographic areas where mosquitoes are present. Cats of any age and breed can be affected, but purebred cats may have a higher rate of occurrence ([52](#_ENREF_52), [53](#_ENREF_53)).

***3.4.2. Clinical signs***

MBH is a visually distinctive feline allergic skin disease (Fig. 1) characterised by initial erythematous papules and in chronic cases by pruritic, crusted, ulcerated dermatitis reactions on sparsely haired areas like the nasal planum or pinnae ([54-56](#_ENREF_54)). Less commonly the paw pads, eyelids, chin, and lips of cats may be affected ([57](#_ENREF_57)). Peripheral lymphadenopathy and moderate fever associated with blood eosinophilia are commonly seen ([54](#_ENREF_54)).

***3.4.3. Allergen sources and allergen molecules***

Allergic reactions, presumably IgE-mediated type I hypersensitivity, occur to saliva antigens of most species of *Anopheles* spp. Additional factors may be involved in the formation of delayed papular reactions, including presence of other secondary parasites like filarids and associated bacteria ([55](#_ENREF_55), [56](#_ENREF_56)).

***3.4.4. Diagnosis***

Accurate diagnosis depends on history, physical findings, and histopathologic evaluation. Differential diagnoses include other allergies, eosinophilic plaque, lupus erythaematosus, squamous cell carcinoma, feline herpesvirus-1 infection or bacterial infections ([55](#_ENREF_55), [56](#_ENREF_56)). An interstitial, interfollicular eosinophilic inflammation with characteristic collagen degeneration and eosinophilic folliculitis is seen on histopathology ([55](#_ENREF_55), [57](#_ENREF_57)).

***3.4.5. Prophylaxis, management, and therapy***

To prevent mosquito bites, cats can be kept indoors, either permanently or at least at dusk and dawn. Repellents can be used as long as they are registered for use in cats, e.g. a flumethrin-containing collar. Symptomatic treatment with glucocorticoids may be needed ([52](#_ENREF_52), [55](#_ENREF_55)).

**3.5. Eosinophilic furunculosis in dogs**

***3.5.1. Epidemiology***

Canine eosinophilic furunculosis predominantly affects the nasal area and face. It has an acute onset and is highly responsive to glucocorticoids ([58](#_ENREF_58)). The exact aetiology of the condition is unclear; presumably, acute allergic reactions to bites from venous arthropods or insects are incriminated ([59](#_ENREF_59), [60](#_ENREF_60)). Inquisitive dogs and breeds (e.g. terriers) tend to be affected more frequently. Retrospective studies revealed a 76% incidence in large-breed dogs, with 47% and 81% younger than 2 and 4 years, respectively ([61](#_ENREF_61), [62](#_ENREF_62)).

***3.5.2. Clinical signs***

Clinical signs include peracute development of papules, pustules and crusts affecting face, pinnae and in particular muzzle/bridge of the nose ([63](#_ENREF_63)), having led to the term ‘face rot’. Rarely, the abdomen or chest may also be affected and the condition can be painful or pruritic with localised swelling, ulceration, haemorrhage and fever. Permanent scarring is possible ([64](#_ENREF_64)).

***3.5.3. Allergen sources and allergen molecules***

Individual allergens or molecules responsible for eliciting the clinical signs of eosinophilic furunculosis in dogs or cats have not yet been described.

***3.5.4. Diagnosis***

Diagnosis is achieved through history, clinical examination, cytology and histology. Differential diagnoses include bacterial pyoderma or demodicosis ([63](#_ENREF_63)). Many patients also have eosinophilia, and in one study, 50% of cases also had gastrointestinal symptoms ([57](#_ENREF_57), [58](#_ENREF_58), [64](#_ENREF_64)).

***3.5.5. Prophylaxis, management, and therapy***

Canine eosinophilic furunculosis is very responsive to glucocorticoid therapy. The earlier therapy is initiated, the faster the healing. Without therapy, complete resolution may take several months. If a secondary infection is observed on cytology or histopathology, the use of systemic antibiotics is appropriate ([57](#_ENREF_57), [58](#_ENREF_58)).

**4. Respiratory allergies to insects**

**4.1. Respiratory allergies to insects in human beings**

***4.1.1. Epidemiology***

Airborne insect allergens from housefly, mosquito, cockroach and others may be a cause of allergic rhinitis or bronchial asthma ([65-67](#_ENREF_65)). A recent observation is the seasonal allergy to the Asian ladybug (*Harmonia axyridis*), with a prevalence of up to 10% in endemic areas ([68](#_ENREF_68)). In Europe and the US, most cases of respiratory allergies to insects are due to occupational exposure during insect breeding for feeding reptiles and other larger animals, e.g. in zoos ([69](#_ENREF_69), [70](#_ENREF_70)) or pet shops ([71](#_ENREF_71)). Among people occupied with fish aquaria, where insect larvae are used as fish food, approximately 20% showed allergy to *Chironomidae* larvae and midges ([72](#_ENREF_72)). Recently, an overall sensitisation rate of 6% to fruit fly (*Drosophila melanogaster*) with a clear relationship to frequency and/or intensity of exposure was found in scientific researchers ([73](#_ENREF_73)). Of people professionally exposed to locusts, 60% ([74](#_ENREF_74), [75](#_ENREF_75)), and of silk workers, 34% ([76](#_ENREF_76)) were affected by respiratory allergy to insects. On average, 25-50% of (professionally) exposed people develop respiratory symptoms to insects ([74](#_ENREF_74), [77](#_ENREF_77)).

More recently, trends towards keeping reptiles as pets represent a new indoor source of insect exposure, as species such as grasshoppers or locusts are used as food ([78](#_ENREF_78)).

***4.1.2. Clinical signs***

The most prevalent signs of respiratory allergy to the different life-stages and body parts of insects in human patients are rhinoconjunctivitis, stridor, asthma and urticaria; the latter however is most likely due to skin contact ([74](#_ENREF_74), [78](#_ENREF_78)).

***4.1.3. Allergen sources and allergen molecules***

Among the many detected molecules thought to be responsible for respiratory insect allergies, only few have been identified ([79](#_ENREF_79)), the most important being panallergens like tropomyosin (35-38 kDa) and arginine kinase (40 kDa). These allergens are cross-reactive with house dust mite, crustaceans and insects like silkworm, cockroach and Indian meal moth ([77](#_ENREF_77)). Recently, the allergen thiol peroxiredoxin was reported in silkworms ([80](#_ENREF_80)), and from silkworm pupae Bom m 9 (30 kDa, high amino acid similarity to microvitellogenin), vitellogenin, chitinase, triosephosphate isomerase, heat shock protein and chymotrypsin inhibitor ([81](#_ENREF_81)). In the Asian ladybug, Har a 1 and Har a 2 have been characterised as major allergens ([68](#_ENREF_68)).

***4.1.4. Diagnosis***

Apart from the history, detailed (molecular) diagnosis is possible for specific IgE against mites, cockroaches, fire ants, horse fly, mosquitos, grain beetle and others, however, for sensitisation to more “exotic” insects like locusts, crickets or certain flies, prick-to-prick testing might be necessary.

***4.1.5. Prophylaxis, management, and therapy***

The most efficient step is the avoidance of allergen sources, which might pose a special problem if the contact is profession-related. Primary and secondary prevention might be reached by working under an exhaust hood and using dusk filter masks. Immunotherapy is routinely performed for house dust mites, and in clinical trials for cockroaches ([82](#_ENREF_82)), individually or mixed with housefly and mosquito ([66](#_ENREF_66)).

**4.2. Respiratory allergies to insects in animals**

There are no reports of inhalant allergy to insects in companion animals. In horses, there is speculation that the syndrome variously termed “recurrent airway obstruction” or “equine asthma” (partially analogous to human chronic obstructive pulmonary disease) may result from allergic sensitisation, though whether insects, moulds, pollens, or a combination may be involved has not been elucidated.

**5. Allergies to ingested insects**

**5.1. Allergies to ingested insects in human beings**

***5.1.1. Background and epidemiology***

Insects represent an alternative dietary protein source for both people and animals. Over 2000 species are consumed globally by ~2 billion people, particularly in Asia, Latin America, and Africa ([83](#_ENREF_83" \o "van Huis, 2013 #284)). Additionally, an estimated 500 grams of insect material/person are ingested unintentionally per year ([84](#_ENREF_84" \o "FDA, 1995; Revised 1997 and 1998. #2562)). For allergy to ingested insects (reviewed in ([85](#_ENREF_85))), no reliable prevalence numbers are available. A few reports describe allergy to silkworm, mealworm, larvae of the mealworm beetle, caterpillars, locusts, *Bruchus lentis*, grasshoppers, sago worm, cicada, bee and *Clanis bilineata*. Ingestion of insects caused allergic symptoms in 7.6% of entomophagists in Laos ([86](#_ENREF_86)) and was the cause in 18% of anaphylactic reactions to food in China ([87](#_ENREF_87)).

Allergy following ingestion of insects can represent either primary sensitization, or cross-reactivity with other allergens like those of shrimp or HDM. Cross-reactivity/co-sensitisation was assessed for mealworm, grasshopper, cricket, moth, black soldier fly, termite, fruit fly, stable flies, locust and cockroach, mostly with crustacean and/or HDM allergic patients ([75](#_ENREF_75), [88-91](#_ENREF_88)) (Pali-Schöll et al, MS in revision). In a double-blind placebo-controlled food-challenge (DBPCFC) study with 15 shrimp allergic patients, clinically relevant co-sensitisation to mealworm in 13 could be detected ([92](#_ENREF_92)). Co-sensitisation to cricket, giant mealworm, lesser mealworm, grasshopper, wax moth, and black soldier fly could be demonstrated *in vitro* in 15 shrimp allergic patients ([93](#_ENREF_93)). In some cases, allergic reactions occurred upon first ingestion, suggestive of cross-sensitisation e.g. via shrimp ([92](#_ENREF_92), [94](#_ENREF_94), [95](#_ENREF_95)). In contrast, a DBPCFC study confirmed *de novo* sensitisation in mealworm breeders ([94](#_ENREF_94)).

***5.1.2. Clinical signs***

Clinical reactions to insect-containing food ranged from mild localised reactions to more severe systemic reactions like anaphylactic shock within a few minutes to 6 hours. Symptoms can be classified as cutaneous (e.g. urticaria, pruritus, rash, flushing, angioedema), gastrointestinal (e.g. abdominal pain, nausea, vomiting, diarrhoea) and respiratory (e.g. asthma, dyspnoea).

***5.1.3. Allergen sources and allergen molecules***

Various allergenic proteins have been identified (reviewed in ([85](#_ENREF_85" \o "de Gier, 2018 #3134))). The best-characterized molecules are the pan-allergens tropomyosin and arginine kinase, >70% homologous to those from shrimp and HDM. Other insect allergens include myosin light- and heavy-chain, troponin C, hexamerin and larval cuticle protein ([79](#_ENREF_79" \o "Sub-Committee,  #4244), [94](#_ENREF_94" \o "Broekman, 2017 #886)), with a 35-95% homology between different insect species and crustaceans (e.g. shrimp). Novel mealworm allergens were described: larval cuticle protein A1A, A2B and A3A, which are different from the allergens known to cause cross-reactivity. Exposure different from ingestion (e.g. inhalation or skin contact) could have played a role in the sensitisation process.

***5.1.4. Diagnosis***

DBPCFC was previously used to diagnose food allergy to mealworm ([93](#_ENREF_93), [94](#_ENREF_94)). Most other studies used IgE-binding tests like immunoblot, ELISA or RAST, or functional skin prick tests and BAT ([96](#_ENREF_96), [97](#_ENREF_97)) with extracts of insects.

For detection of insect-specific IgE relevant in ingestion, some commercially available diagnostic materials are available, e.g. whole-body extracts of American and German cockroach, silkworm, or mealworm ([94](#_ENREF_94)), but no individual recombinant allergens. Skin prick test solutions are also available for different insects, like black carpenter and fire ant, caddis fly, American and German cockroach, deer fly, flea, housefly, mayfly, mosquito, and moth, with unknown certainty for insect food allergy diagnosis.

***5.1.5. Prophylaxis, management, and therapy***

For insect ingestion allergy, preventive or causative options are limited. The only option is to treat the symptoms with antihistamines and/or corticosteroids and/or epinephrine (during anaphylactic reactions).

Normal kitchen processes (cooking, boiling, freezing, frying) could not completely prevent binding of crossreactive IgE from shrimp-allergic patients to mealworm proteins ([98](#_ENREF_98" \o "van Broekhoven, 2016 #321), [99](#_ENREF_99" \o "Broekman, 2015 #4)). However, more efficient food processing like enzymatic hydrolysis and autoclaving of migratory locust depleted the IgE-binding capacity as well as the skin prick test-reactivity of shrimp-allergic patients completely (Pali-Schöll et al., MS in revision).

The avoidance of eating insect-containing products therefore represents the most important management step, especially when shrimp or HDM allergy has been diagnosed. This information needs to be distributed to doctors and the public, and industry must be required to carefully label all products, as indicated by the recent Novel Food EU directive (special reference to insect food allergies) ([100](#_ENREF_100)).

**5.2. Food allergy to insects in animals**

Insect meal is included as a substitute for soy and fish meal in feed for fish ([101](#_ENREF_101)) and poultry ([102](#_ENREF_102), [103](#_ENREF_103)), and is envisaged also for farm animals like pigs and cattle. The use of insects in dog and cat food is a developing market especially in the US. Today, insect-based food for dogs with mealworm larvae as the sole animal protein source is advertised as a novel-protein, hypoallergenic food for dogs and cats sensitive to conventional protein sources. In a non-blinded case series of 15 dogs with food-induced atopic dermatitis, a commercially available dry food based on mealworm was tested; 12/15 dogs showed improvement of skin lesions and 8/15 had reduced itching. However, 2/15 showed worsening of their symptoms probably attributed to the insect-based food (Mueller RS et al, manuscript in revision).

**6. Knowledge gaps**

Though it is clear that hypersensitivities to insects can occur via different routes and to different allergens, and some of the relevant facts have been elucidated already, many are still unclear and need to be investigated in future research activities (Box 1).

Although the diagnosis of insect sting allergy in human beings is very advanced and allergen-specific immunotherapy highly effective, to date it is unknown which factors or sensitization profiles determine the severity of disease and therapeutic outcome. Also, information about the epidemiology of allergies to insect bites from the different species in people is extremely limited. Moreover, little is known about cross-reactivity between allergens of biting insects and its clinical relevance.

Inclusion of edible insects in the diet of both people and animals is not a new phenomenon, but appears to be increasing as the search for sustainable dietary protein sources continues. Considering already revealed cross-reactivities, the modern trend to eat and feed insects in a concentrated form as a protein source could easily lead to a higher incidence of food-allergic reactions. Knowledge gaps exist regarding these cross-reactivities; for example, we do not know if allergy to ingested insects will also lead to more allergies, or worsening existing allergies. Furthermore, we do not know as yet if HDM allergic patients without shrimp allergy will clinically react to mealworm and other insects. There may be certain cross-reactivities among different insects or insect species, and, apart from mealworm it is not known whether edible insects can cause *de novo* sensitization and resulting clinical signs of food allergy.

In veterinary allergy, for canine eosinophilic furunculosis, etiology of the condition is still unclear with regards to different breeds, as well as the precise role of insect allergens. In cats, it is unknown if mosquito-bite hypersensitivity may be caused or worsened by cross-reaction or co-sensitization with other insects. Importantly, flea salivary antigens are not completely defined as to their number, molecular structure, and relative importance in different species and individuals. This knowledge could enable production in recombinant form, and establishment of desensitization protocols. This approach, if successful, would be much more sensible, safe and environmentally friendly then constant use of insecticides on all animals in a household.

Knowledge has to be gained regarding the true prevalence of allergies to edible insects in our companion animals when applied in feed. Different insect species and certain parts of insects need to be characterized with regards to their allergenic potential. Most important, all used insect species and protein sources need to be evaluated for allergenicity in the processed form that is finally used for consumption.

**Synopsis**

Allergic reactions to different insect species evoked by different routes of insect encounter are observed in people and companion animals. According to the route of exposure, symptoms in human beings and animals can range from skin reactions to rhinoconjunctivitis and asthma, to even life-threatening anaphylactic reactions. Some specific syndromes like cutaneous insect bite hypersensitivity (such as with fleas and *Culicoides* spp.) are mainly observed in animals, whereas respiratory allergies (mainly from occupational exposure) are primarily seen in people. For both human beings and animals, allergies to insect venoms are the best described, whereas the field of insects as novel dietary ingredients, and potential resulting food allergies, is only minimally investigated. As a consequence, those individual major allergens from insects, important for diagnosis and treatment, have been detailed only for stinging insects. Further research regarding the pathogenesis of insect allergies in animals, and the investigation of allergenic molecules, is needed for optimal diagnosis, prevention and treatment of insect allergies in pets and their human companions.**Box 1: Future research needs on insect hypersensitivities**

|  |  |
| --- | --- |
| **Topic** | **Future research needs** |
| Insect sting allergy in humans | * Development of diagnostic tools to better differentiate allergies to different *Vespoidea*species * Identification of biomarkers that allow the prediction of success of venom allergen-specific immunotherapy * Elucidation of reasons for therapeutic failure in particular patients |
| Insect bite allergy in humans | * Development of advanced differential diagnostics of insect bite allergies in humans * Definition of standardized therapeutic strategies for the treatment of insect bite allergies in humans * Identification of relevant allergens and elucidation of cross-reactivity between allergens of different species |
| Canine eosinophilic furunculosis | * Development of diagnostic methods to understand the involvement of insect allergens in this disease |
| Mosquito bite hypersensitivity in cats | * Identification of allergens and cross-reactivity between allergens of different insect species affecting cats |
| Flea bite hypersensitivity in dogs and cats | * Flea salivary antigens need to be characterized, sequenced and produced in recombinant form for desensitization protocols |
| Edible insects in human diet | * A good double blind placebo controlled food challenge with different insects snacks is needed with HDM-, shrimp- and insects-allergic patients * Scientifically validated and harmonized methods to predict *de novo* sensitization of novel proteins such as insects |
| Edible insects in veterinary diet | * Definition of actual food allergy prevalence to insects in companion animals * Characterization of allergens relevant in allergy to edible insects * Identification of food processing methods to reduce presumptive allergenic potential |

**Author contributions**

IPS set up the outline, coordinated the writing, and authored the veterinary sections on allergy against insect sting, inhalation and ingestion; KV contributed the part on human insect food allergies; SB wrote the part on human insect sting/venom and bite allergies as well as the molecular allergen section (incl. tables); EJJ contributed the part on pathogenesis and together with SB authored the molecular allergen section and tables, and helped in the overall manuscript writing; JJ, CR and EM contributed the veterinary sections of epidemiology, clinical signs, pathogenesis and treatment for horses; RSM and AAS authored the sections about flea allergy in dogs and cats, mosquito-bite hypersensitivity in cats, and eosinophilic furunculosis in dogs; DJD did the final reviewing and editing of all sections. All authors critically revised and edited the manuscript and approved the final version.

**Conflicts of interest**

The authors declare no conflict of interest.

**References**

1. Forrester JA, Weiser TG, Forrester JD. An Update on Fatalities Due to Venomous and Nonvenomous Animals in the United States (2008-2015). *Wilderness Environ Med* 2018;**29**(1):36-44.

2. Arikan-Ayyildiz Z, Isik S, Babus S, Ucku R, Caglayan-Sozmen S, Karaman O, et al. Allergic reactions to Hymenoptera stings in Turkish school children. *Allergol Immunopathol (Madr)* 2016;**44**(1):41-45.

3. Blum S, Gunzinger A, Muller UR, Helbling A. Influence of total and specific IgE, serum tryptase, and age on severity of allergic reactions to Hymenoptera stings. *Allergy* 2011;**66**(2):222-228.

4. Einhorn L, Hofstetter G, Brandt S, Hainisch EK, Fukuda I, Kusano K, et al. Molecular allergen profiling in horses by microarray reveals Fag e 2 from buckwheat as a frequent sensitizer. *Allergy* 2018;**73**(7):1436-1446.

5. Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, et al. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). *Clin Transl Allergy* 2017;**7**:5.

6. Becerril-Angeles M, Nunez-Velazquez M, Marin-Martinez J, Grupo del Programa Nacional de Control de la Abeja Africanizada S. [Assessment of hypersensitivity to honey-bee venom in beekeepers by skin tests]. *Rev Alerg Mex* 2013;**60**(4):164-167.

7. Marichal T, Starkl P, Reber LL, Kalesnikoff J, Oettgen HC, Tsai M, et al. A beneficial role for immunoglobulin E in host defense against honeybee venom. *Immunity* 2013;**39**(5):963-975.

8. Kochuyt AM, Van Hoeyveld EM, Stevens EA. Prevalence and clinical relevance of specific immunoglobulin E to pollen caused by sting- induced specific immunoglobulin E to cross-reacting carbohydrate determinants in Hymenoptera venoms. *Clin Exp Allergy* 2005;**35**(4):441-447.

9. Fitzgerald KT, Flood AA. Hymenoptera stings. *Clin Tech Small Anim Pract* 2006;**21**(4):194-204.

10. Buckley GJ, Corrie C, Bandt C, Schaer M. Kidney injury in a dog following bee sting-associated anaphylaxis. *Can Vet J* 2017;**58**(3):265-269.

11. Bilo BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. *Curr Opin Allergy Clin Immunol* 2008;**8**(4):330-337.

12. Jennings A, Duggan E, Perry IJ, Hourihane JO. Epidemiology of allergic reactions to hymenoptera stings in Irish school children. *Pediatr Allergy Immunol* 2010;**21**(8):1166-1170.

13. Bilo MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. *Clin Exp Allergy* 2009;**39**(10):1467-1476.

14. Antonicelli L, Bilo MB, Bonifazi F. Epidemiology of Hymenoptera allergy. *Curr Opin Allergy Clin Immunol* 2002;**2**(4):341-346.

15. Worm M, Moneret-Vautrin A, Scherer K, Lang R, Fernandez-Rivas M, Cardona V, et al. First European data from the network of severe allergic reactions (NORA). *Allergy* 2014;**69**(10):1397-1404.

16. Golden DB. Insect sting anaphylaxis. *Immunol Allergy Clin North Am* 2007;**27**(2):261-272, vii.

17. Settipane GA, Newstead GJ, Boyd GK. Frequency of Hymenoptera allergy in an atopic and normal population. *J Allergy Clin Immunol* 1972;**50**(3):146-150.

18. Sturm GJ, Varga EM, Roberts G, Mosbech H, Bilo MB, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. *Allergy* 2018;**73**(4):744-764.

19. Severino M, Bonadonna P, Passalacqua G. Large local reactions from stinging insects: from epidemiology to management. *Curr Opin Allergy Clin Immunol* 2009;**9**(4):334-337.

20. Blank S, Bilo MB, Ollert M. Component-resolved diagnostics to direct in venom immunotherapy: Important steps towards precision medicine. *Clin Exp Allergy* 2018;**48**(4):354-364.

21. Shmuel DL, Cortes Y. Anaphylaxis in dogs and cats. *J Vet Emerg Crit Care (San Antonio)* 2013;**23**(4):377-394.

22. Cowell AK. Management of bee and other Hymenopter stings. In: Bonagura JD, Kirk RW, editors. Kirk's current veterinary therapy. Philadelphia: W.B. Saunders; 1995.

23. Hemmer W. Allergische Reaktionen auf andere Insekten als Hymenopteren. *Allergologie* 2014;**37**(9):374-382.

24. Platts-Mills TA, Commins SP. Emerging antigens involved in allergic responses. *Curr Opin Immunol* 2013;**25**(6):769-774.

25. Ray JN, Pence HL. Ladybug hypersensitivity: report of a case and review of literature. *Allergy Asthma Proc* 2004;**25**(2):133-136.

26. Peng Z, Estelle F, Simons R. Mosquito allergy and mosquito salivary allergens. *Protein Pept Lett* 2007;**14**(10):975-981.

27. Reunala T, Brummer-Korvenkontio H, Palosuo T. Are we really allergic to mosquito bites? *Ann Med* 1994;**26**(4):301-306.

28. Hemmer W, Focke M, Vieluf D, Berg-Drewniok B, Gotz M, Jarisch R. Anaphylaxis induced by horsefly bites: identification of a 69 kd IgE-binding salivary gland protein from Chrysops spp. (Diptera, Tabanidae) by western blot analysis. *J Allergy Clin Immunol* 1998;**101**(1 Pt 1):134-136.

29. Reiter N, Reiter M, Altrichter S, Becker S, Kristensen T, Broesby-Olsen S, et al. Anaphylaxis caused by mosquito allergy in systemic mastocytosis. *Lancet* 2013;**382**(9901):1380.

30. Klotz JH, Dorn PL, Logan JL, Stevens L, Pinnas JL, Schmidt JO, et al. "Kissing bugs": potential disease vectors and cause of anaphylaxis. *Clin Infect Dis* 2010;**50**(12):1629-1634.

31. Peng Z, Beckett AN, Engler RJ, Hoffman DR, Ott NL, Simons FE. Immune responses to mosquito saliva in 14 individuals with acute systemic allergic reactions to mosquito bites. *J Allergy Clin Immunol* 2004;**114**(5):1189-1194.

32. Brown A, Griffitts THD, Erwin S, Dyrenforth LY. Arthus phenomenon from mosquito bites. Report of a case with experimental studies. *Journal of Allergy* 1938;**10**(3):311.

33. deShazo RD, Feldlaufer MF, Mihm MC, Jr., Goddard J. Bullous reactions to bedbug bites reflect cutaneous vasculitis. *Am J Med* 2012;**125**(7):688-694.

34. Kleine-Tebbe J, Heinatz A, Graser I, Dautel H, Hansen GN, Kespohl S, et al. Bites of the European pigeon tick (Argas reflexus): Risk of IgE-mediated sensitizations and anaphylactic reactions. *J Allergy Clin Immunol* 2006;**117**(1):190-195.

35. Karppinen A, Brummer-Korvenkontio H, Petman L, Kautiainen H, Herve JP, Reunala T. Levocetirizine for treatment of immediate and delayed mosquito bite reactions. *Acta Derm Venereol* 2006;**86**(4):329-331.

36. Ariano R, Panzani RC. Efficacy and safety of specific immunotherapy to mosquito bites. *Eur Ann Allergy Clin Immunol* 2004;**36**(4):131-138.

37. Berkovitz S, Hill N, Radcliffe M, Ambler G. A randomised, double-blind pilot study of enzyme-potentiated desensitisation for prophylaxis of large local reactions to mosquito bites. *J Allergy (Cairo)* 2012;**2012**:106069.

38. Schaffartzik A, Hamza E, Janda J, Crameri R, Marti E, Rhyner C. Equine insect bite hypersensitivity: what do we know? *Vet Immunol Immunopathol* 2012;**147**(3-4):113-126.

39. Noli C, Foster AP, Rosenkrantz W. Veterinary allergy; 2014.

40. Hamza E, Mirkovitch J, Steinbach F, Marti E. Regulatory T cells in early life: comparative study of CD4+CD25high T cells from foals and adult horses. *PLoS One* 2015;**10**(3):e0120661.

41. van der Meide NM, Savelkoul HF, Meulenbroeks C, Ducro BJ, Tijhaar E. Evaluation of a diagnostic ELISA for insect bite hypersensitivity in horses using recombinant Obsoletus complex allergens. *Vet J* 2014;**200**(1):31-37.

42. Marti E, Wang X, Jambari NN, Rhyner C, Olzhausen J, Perez-Barea JJ, et al. Novel in vitro diagnosis of equine allergies using a protein array and mathematical modelling approach: a proof of concept using insect bite hypersensitivity. *Vet Immunol Immunopathol* 2015;**167**(3-4):171-177.

43. Jonsdottir S, Svansson V, Stefansdottir SB, Sch¸pbach G, Rhyner C, Marti E, et al. A preventive immunization approach against insect bite hypersensitivity: Intralymphatic injection with recombinant allergens in Alum or Alum and monophosphoryl lipid A. *Veterinary Immunology and Immunopathology* 2016;**172**:14-20.

44. Jonsdottir S, Svansson V, Stefansdottir SB, Mantyla E, Marti E, Torsteinsdottir S. Oral administration of transgenic barley expressing a Culicoides allergen induces specific antibody response. *Equine Vet J* 2017;**49**(4):512-518.

45. Fettelschoss-Gabriel A, Fettelschoss V, Thoms F, Giese C, Daniel M, Olomski F, et al. Treating insect-bite hypersensitivity in horses with active vaccination against IL-5. *J Allergy Clin Immunol* 2018:in press.

46. Rust MK. The Biology and Ecology of Cat Fleas and Advancements in Their Pest Management: A Review. *Insects* 2017;**8**(4).

47. Halos L, Beugnet F, Cardoso L, Farkas R, Franc M, Guillot J, et al. Flea control failure? Myths and realities. *Trends Parasitol* 2014;**30**(5):228-233.

48. Diesel A. Cutaneous Hypersensitivity Dermatoses in the Feline Patient: A Review of Allergic Skin Disease in Cats. *Vet Sci* 2017;**4**(2).

49. Lee SE, Johnstone IP, Lee RP, Opdebeeck JP. Putative salivary allergens of the cat flea, Ctenocephalides felis felis. *Vet Immunol Immunopathol* 1999;**69**(2-4):229-237.

50. McDermott MJ, Weber E, Hunter S, Stedman KE, Best E, Frank GR, et al. Identification, cloning, and characterization of a major cat flea salivary allergen (Cte f 1). *Mol Immunol* 2000;**37**(7):361-375.

51. Laffort-Dassot C, Carlotti DN, Pin D, Jasmin P. Diagnosis of flea allergy dermatitis: comparison of intradermal testing with flea allergens and a FcepsilonRI alpha-based IgE assay in response to flea control. *Vet Dermatol* 2004;**15**(5):321-330.

52. Nagata M, Ishida T. Cutaneous reactivity to mosquito bites and its antigens in cats. *Vet Dermatol* 1997;**8**:19-26.

53. Mueller RS, Janda J, Jensen-Jarolim E, Rhyner C, Marti E. Allergens in veterinary medicine. *Allergy* 2016;**71**(1):27-35.

54. Wilkinson GT, Bate MJ. A possible further clinical manifestation of the feline eosinophilic granuloma complex. *JAAHA* 1984;**20**:235-331.

55. Mason KV, Evans AG. Mosquito bite-caused eosinophilic dermatitis in cats. *J Am Vet Med Assoc* 1991;**198**(12):2086-2088.

56. Johnstone AC, Graham DG, Andersen HJ. A seasonal eosinophilic dermatitis in cats. *N Z Vet J* 1992;**40**(4):168-172.

57. Scott DW, Muller GH, Kirk RW, Miller WH, Griffin CE. Muller & Kirk's small animal dermatology. Philadelphia: W.B. Saunders; 2001.

58. Miller WH, Griffin CE, Campbell KL. Muller and Kirk’s Small Animal Dermatology; 2013.

59. Mauldin EA, Peters-Kennedy J. Jubb, Kennedy & Palmer's Pathology of Domestic Animals. 6 ed; 2016.

60. Mauldin EA, Palmeiro BS, Goldschmidt MH, Morris DO. Comparison of clinical history and dermatologic findings in 29 dogs with severe eosinophilic dermatitis: a retrospective analysis. *Vet Dermatol* 2006;**17**(5):338-347.

61. Bloom PB. Canine and feline eosinophilic skin diseases. *The Veterinary clinics of North America. Small animal practice* 2006;**36**(1):141-160.

62. Gross TL. Canine eosinophilic furuncolosis of the face. In: Ihrke PJ, Mason IS, White SD, editors. Advances in veterinary dermatology. Oxford: Pergamon; 1993. p. 239-246.

63. Curtis CF, Bond R, Blunden AS, Thomson DG, McNeil PE, Whitbread TW. Canine eosinophilic folliculitis and furunculosis in three cases. *J Small Anim Pract* 1995;**36**(3):119-123.

64. Paterson S, Paterson S, Paterson S. Manual of skin diseases of the dog and cat. Oxford: Blackwell Pub.; 2008.

65. Kumar R, Gupta N, Kanuga J, Kanuga M. A Comparative Study of Skin Prick Test versus Serum-Specific IgE Measurement in Indian Patients with Bronchial Asthma and Allergic Rhinitis. *Indian J Chest Dis Allied Sci* 2015;**57**(2):81-85.

66. Srivastava D, Singh BP, Arora N, Gaur SN. Clinico-immunologic study on immunotherapy with mixed and single insect allergens. *J Clin Immunol* 2009;**29**(5):665-673.

67. Focke M, Hemmer W, Wohrl S, Gotz M, Jarisch R, Kofler H. Specific sensitization to the common housefly (Musca domestica) not related to insect panallergy. *Allergy* 2003;**58**(5):448-451.

68. Goetz DW. Seasonal inhalant insect allergy: Harmonia axyridis ladybug. *Curr Opin Allergy Clin Immunol* 2009;**9**(4):329-333.

69. Rauschenberg R, Bauer A, Beissert S, Spornraft-Ragaller P. Occupational immediate-type allergy to locusts in a zookeeper. *J Dtsch Dermatol Ges* 2015;**13**(2):157-158.

70. Bregnbak D, Friis UF, Zachariae C, Menne T, Johansen JD. Protein contact dermatitis caused by worms and insects used to feed exotic birds. *Contact Dermatitis* 2014;**70**(1):64-66.

71. Bygum A, Bindslev-Jensen C. [Mealworm allergy]. *Ugeskr Laeger* 1997;**159**(44):6532-6533.

72. Baur X. Chironomid midge allergy. *Arerugi* 1992;**41**(2 Pt 1):81-85.

73. Jones M, Blair S, MacNeill S, Welch J, Hole A, Baxter P, et al. Occupational allergy to fruit flies (Drosophila melanogaster) in laboratory workers. *Occup Environ Med* 2017;**74**(6):422-425.

74. Lopata AL, Fenemore B, Jeebhay MF, Gade G, Potter PC. Occupational allergy in laboratory workers caused by the African migratory grasshopper Locusta migratoria. *Allergy* 2005;**60**(2):200-205.

75. Tee RD, Gordon DJ, Hawkins ER, Nunn AJ, Lacey J, Venables KM, et al. Occupational allergy to locusts: an investigation of the sources of the allergen. *J Allergy Clin Immunol* 1988;**81**(3):517-525.

76. Uragoda CG, Wijekoon PN. Asthma in silk workers. *J Soc Occup Med* 1991;**41**(3):140-142.

77. Hemmer W. Insects as a cause for allergic reactions. In: Aspöck H, editor. Krank durch Arthropoden: Denisia; 2010. p. 381-409.

78. Jensen-Jarolim E, Pali-Scholl I, Jensen SA, Robibaro B, Kinaciyan T. Caution: Reptile pets shuttle grasshopper allergy and asthma into homes. *World Allergy Organ J* 2015;**8**(1):24.

79. Sub-Committee WIAN. Allergen nomenclature. [cited 2018 6 June]; Available from: <http://www.allergen.org/>

80. Wang H, Hu W, Liang Z, Zeng L, Li J, Yan H, et al. Thiol peroxiredoxin, a novel allergen from Bombyx mori, modulates functions of macrophages and dendritic cells. *Am J Transl Res* 2016;**8**(12):5320-5329.

81. Zuo J, Lei M, Yang R, Liu Z. Bom m 9 from Bombyx mori is a novel protein related to asthma. *Microbiol Immunol* 2015;**59**(7):410-418.

82. Bassirpour G, Zoratti E. Cockroach allergy and allergen-specific immunotherapy in asthma: potential and pitfalls. *Curr Opin Allergy Clin Immunol* 2014;**14**(6):535-541.

83. van Huis A, Van Itterbeeck J, Klunder H, Mertens E, Halloran A, Muir G, et al. Edible insects: Future prospects for food and feed security. *FAO Forestry Paper* 2013;**171**.

84. FDA. The Food Defect Action Levels. Levels of natural or unavoidable defects in foods that present no health hazards for humans. In: Administraion USFaD, editor. Defect Levels Handbook. Silver Spring, MD; 1995; Revised 1997 and 1998.

85. de Gier S, Verhoeckx K. Insect (food) allergy and allergens. *Mol Immunol* 2018;**100**:82-106.

86. Barennes H, Phimmasane M, Rajaonarivo C. Insect Consumption to Address Undernutrition, a National Survey on the Prevalence of Insect Consumption among Adults and Vendors in Laos. *PLoS One* 2015;**10**(8):e0136458.

87. Ji K, Chen J, Li M, Liu Z, Wang C, Zhan Z, et al. Anaphylactic shocks and lethal anaphylaxis caused by food consumption in China. *Trends in Food Science & Technology* 2009;**20**:227-231.

88. Leung PS, Chow WK, Duffey S, Kwan HS, Gershwin ME, Chu KH. IgE reactivity against a cross-reactive allergen in crustacea and mollusca: evidence for tropomyosin as the common allergen. *J Allergy Clin Immunol* 1996;**98**(5 Pt 1):954-961.

89. Srinroch C, Srisomsap C, Chokchaichamnankit D, Punyarit P, Phiriyangkul P. Identification of novel allergen in edible insect, Gryllus bimaculatus and its cross-reactivity with Macrobrachium spp. allergens. *Food Chem* 2015;**184**:160-166.

90. Phiriyangkul P, Srinroch C, Srisomsap C, Chokchaichamnankit D, Punyarit P. Effect of Food Thermal Processing on Allergenicity Proteins in Bombay Locust (Patanga Succincta). *Int J Food Engeneer* 2015;**1**(1):23-28.

91. Barletta B, Pini C. Does occupational exposure to insects lead to species-specific sensitization? *Allergy* 2003;**58**(9):868-870.

92. Broekman H, Verhoeckx KC, den Hartog Jager CF, Kruizinga AG, Pronk-Kleinjan M, Remington BC, et al. Majority of shrimp-allergic patients are allergic to mealworm. *J Allergy Clin Immunol* 2016;**137**(4):1261-1263.

93. Broekman H, Knulst AC, de Jong G, Gaspari M, den Hartog Jager CF, Houben GF, et al. Is mealworm or shrimp allergy indicative for food allergy to insects? *Mol Nutr Food Res* 2017;**61**(9).

94. Broekman H, Knulst AC, den Hartog Jager CF, van Bilsen JHM, Raymakers FML, Kruizinga AG, et al. Primary respiratory and food allergy to mealworm. *J Allergy Clin Immunol* 2017;**140**(2):600-603 e607.

95. Kung SJ, Fenemore B, Potter PC. Anaphylaxis to Mopane worms (Imbrasia belina). *Ann Allergy Asthma Immunol* 2011;**106**(6):538-540.

96. Liu Z, Xia L, Wu Y, Xia Q, Chen J, Roux KH. Identification and characterization of an arginine kinase as a major allergen from silkworm (Bombyx mori) larvae. *Int Arch Allergy Immunol* 2009;**150**(1):8-14.

97. Zhao X, Li L, Kuang Z, Luo G, Li B. Proteomic and immunological identification of two new allergens from silkworm (Bombyx mori L.) pupae. *Cent Eur J Immunol* 2015;**40**(1):30-34.

98. van Broekhoven S, Bastiaan-Net S, de Jong NW, Wichers HJ. Influence of processing and in vitro digestion on the allergic cross-reactivity of three mealworm species. *Food Chem* 2016;**196**:1075-1083.

99. Broekman H, Knulst A, den Hartog Jager S, Monteleone F, Gaspari M, de Jong G, et al. Effect of thermal processing on mealworm allergenicity. *Mol Nutr Food Res* 2015;**59**(9):1855-1864.

100. Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015

on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. In: Union TEPatCotE, editor. Official Journal of the European Union; 2015.

101. Makkar HT, G., Heuze, V., Ankers, P. . State-of-the-art on use of insects as animal feed. *Animal Feed Science and Technology* 2014;**197**:1-33.

102. Schiavone A, Cullere M, De Marco M. Partial or total replacement of soybean oil by black soldier fly larvae (Hermetia illucens L.) fat in broiler diets: effect on growth performances, feed-choice, blood traits. *Italian Journal of Animal Science* 2017;**16**:93-100.

103. Secci G, Bovera F, Nizza S, Baronti N, Gasco L, Conte G, et al. Quality of eggs from Lohmann Brown Classic laying hens fed black soldier fly meal as substitute for soya bean. *Animal* 2018:1-7.

**Figure legend**

**Figure 1:**

A) Presumptive mosquito-bite hypersensitivity in a cat. Though difficult to confirm this diagnosis, the cat improved with restriction to indoors and a brief course of oral corticosteroids.

B) Insect-bite hypersensitivity in a horse, showing dramatic inflammatory response and excoriations from constant rubbing the area on fence areas.

C) Flea allergy dermatitis in a dog, with classical distribution over the dorsal lumbosacral area.

D) Mixed type hypersensitivities to bite by the blackflies (family Simuliidae) in a male human patient: a) left elbow: painful swelling 24h after a bite, characterized by heat, redness and induration; b) lower right leg: local reactions characterized by hemorrhagic inflammation which may result in central tissue destruction.

Pictures A-C courtesy of Douglas DeBoer and Elizabeth Layne, pictures D courtesy of Erika Jensen-Jarolim.**Table 1:** Overview of the Hymenoptera venom allergens, which are presently listed in the WHO/IUIS Allergen Nomenclature official database (http://www.allergen.org)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Allergen** | **Name/Function** | **MW (kDa)** |  | |
| **American paper wasps (*Polistes annularis*, *P. exclamans*, *P. fuscatus*, *P. metricus*)** | | | |
| Pol a 1, Pol e 1 | Phospholipase A1 | 34 |  | |
| Pol a 2 | Hyaluronidase | 38 |  | |
| Pol e 4 | Serine protease | 33 |  | |
| Pol a 5, Pol e 5, Pol f 5, Pol m 5 | Antigen 5 | 23 |  | |
| **ASIAN NEEDLE ANT (*Pachycondyla chinensis*)** | | | |
| Pac c 3 | Antigen 5 | 23 |  | |
| **Australian jumper ant (*Myrmecia pilosula*)** | | | |
| Myr p 1 | Pilosulin-1 | 7.5/5.5 |  | |
| Myr p 2 | Pilosulin-3 | 8.5/2-4 |  | |
| Myr p 3 | Pilosulin-4.1 | 4 |  | |
| **Bees (*Apis mellifera*, *A. cerana*, *A. dorsata*)** | | | |
| Api m 1, Api c 1, Api d 1 | Phospholipase A2 | 16 |  | |
| Api m 2 | Hyaluronidase | 39 |  | |
| Api m 3 | Acid phosphatase | 43 |  | |
| Api m 4 | Mellitin | 3 |  | |
| Api m 5 | Dipeptidyl peptidase IV | 100 |  | |
| Api m 6 | Protease inhibitor | 8 |  | |
| Api m 7 | CUB serine protease | 39 |  | |
| Api m 8 | Carboxylesterase | 70 |  | |
| Api m 9 | Serine carboxypeptidase | 60 |  | |
| Api m 10 | Icarapin | 50-55 |  | |
| Api m 11.0101 | Major royal jelly protein 8 | 45.1 |  | |
| Api m 11.0201 | Major royal jelly protein 9 | 46.3 |  | |
| Api m 12 | Vitellogenin | 200 |  | |
| **Bumblebee (*Bombus pennsylvanicus*, *B. terrestris*)** | | | |
| Bom p 1, Bom t 1 | Phospholipase A2 | 16 |  | |
| Bom p 4, Bom t 4 | Protease | 27 |  | |
| **European paper wasps (*Polistes dominula*, *P. gallicus*)** | | | |
| Pol d 1, Pol g 1 | Phospholipase A1 | 34 |  | |
| Pol d 2 | Hyaluronidase | 50 |  | |
| Pol d 3 | Dipeptidyl peptidase IV | 100 |  | |
| Pol d 4 | Serine protease | 33 |  | |
| Pol d 5 | Antigen 5 | 23 |  | |
| Pol g 5 | Antigen 5 | 24 |  | |
| **Fire ants (*Solenopsis invicta*, *S. geminata*, *S. richteri*, *S. saevissima*)** | | | |
| Sol i 1 | Phospholipase A1 | 18 |  | |
| Sol i 2 | unknown | 14 |  | |
| Sol g 2, Sol r 2, Sol s 2 | unknown | 13 |  | |
| Sol i 3 | Antigen 5 | 26 |  | |
| Sol g 3, Sol s 3 | unknown | 24 |  | |
| Sol r 3 | Antigen 5 | 24 |  | |
| Sol i 4, Sol g 4 | unknown | 12 |  | |
| **Hornets (*Vespa crabro*, *V. magnifica,* *V. mandarinia*)** | | | |
| Vesp c 1, Vesp m 1 | Phospholipase A1 | 34 |  | |
| Vesp ma 2 | Hyaluronidase | 35 |  | |
| Vesp ma 5 | Antigen 5 | 25 |  | |
| Vesp c 5, Vesp m 5 | Antigen 5 | 23 |  | |
| **Polybia wasp (*Polybia paulista*, *P. scutellaris*)** | | | |
| Poly p 1 | Phospholipase A1 | 34 |  | |
| Poly p 2 | Hyaluronidase | 33 |  | |
| Poly p 5 | Antigen 5 | 21.19 |  | |
| Poly s 5 | Antigen 5 | 23 |  | |
| **White-faced hornet, Yellow hornet (*Dolichovespula maculata*, *D. arenaria*)** | | | |
| Dol m 1 | Phospholipase A1 | 34 |  | |
| Dol m 2 | Hyaluronidase | 42 |  | |
| Dol m 5, Dol a 5 | Antigen 5 | 23 |  | |
| **Yellow jackets (*Vespula vulgaris*, *V. flavopilosa*, *V. germanica*, *V. maculifrons*, *V.* *pensylvanica*, *V. squamosa*, *V. vidua*)** | | | |
| Ves v 1, Ves m 1, Ves s 1 | Phospholipase A1 | 34 |  | |
| Ves v 2.0101 | Hyaluronidase | 45 |  | |
| Ves v 2.0201 | Hyaluronidase(inactive) | 45 |  | |
| Ves m 2 | Hyaluronidase | 46 |  | |
| Ves v 3 | Dipeptidyl peptidase IV | 100 |  | |
| Ves v 5, Ves f 5, Ves g 5, Ves m 5, Ves p 5, Ves s 5, Ves vi 5 | Antigen 5 | 23 |  | |
| Ves v 6 | Vitellogenin | 200 |  | |

**Table 2:** Allergens of biting insects, haematophagous insects listed in the WHO/IUIS Allergen Nomenclature official database (http://www.allergen.org).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Species** | **Allergen** | **Name/Function** | **MW (kDa)** | | |
| **Fam. Glossinidae (tsetse flies)** | | | | | |
| *Glossina morsitans*  (Savannah tsetse fly) | Glo m 5 | Ttsetse antigen 5, CAP protein superfamily member | | | 27 |
| **Fam. Tabanidae (horseflies)** | | | | | |
| *Tabanus yoa* | Tab y 1 | Apyrase | | 70 | |
|  | Tab y 2 | Hyaluronidase | | 35 | |
|  | Tab y 5 | Antigen 5-realted protein, CAP protein superfamily member | | 26 | |
| **Fam. Ceratopogonidae (biting midges)** | | | | | |
| *Forcipomyia taiwana* | For t 1 | Serine/threonine-protein kinase | | 14 | |
|  | For t 2 | Eukaryotic translation initiation factor 3 subunit | | 36 | |
| **Fam. Culicidae (mosquitoes)** | | | | | |
| *Aedes aegypti* | Aed a 1 | Apyrase | | 68 | |
| (yellow-fewer mosquito) | Aed a 2 | Salivary D7 protein | | 37 | |
|  | Aed a 3 | Undefined 30 kDa salivary protein | | 30 | |
|  | Aed a 4 | Glucosidase | | 67 | |
|  | Aed a 5 | Sarcoplasmic Ca+ (EF hand) binding protein | | 28.5 | |
|  | Aed a 6 | Porin 3 | |  | |
|  | Aed a 7 | Undefined protein | |  | |
|  | Aed a 8 | Heat shock cognate protein-70 | |  | |
|  | Aed a 10 | Tropomyosin | | 32 | |
|  | Aed a 11 | Lysosomal aspartic protease | |  | |
| **Fam. Reduviidae (kissing bugs)** | | | | | |
| *Triatoma protracta* | Tria p 1 | Procalin | | 20 | |
| (California kissing bug) |  |  | |  | |
| **Fam. Pulicidae (flees)** | | | | | |
| *Ctenocephalides felis* | Cte f 1 | Salivary protein 1 | | 18 | |
| (cat flea) | Cte f 2 | Antigen 5 | | 27 | |
|  | Cte f 3 | Undefined salivary protein | | 25 | |

**Table 3. Allergens of haematophagous insects relevant for horses that have been characterised at the molecular level.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Species** | **Allergen** | **Name/Function** | **MW (kDa)** | | | **References** | |
| **Fam. Ceratopogonidae (biting midges)** | | | | | | |  |
| *Culicoides nubeculosus* | Cul n 1 | Antigen 5 like \* | | 25.0 | Schaffartzik et al. 2010 | | |
|  |  |  | |  | *Vet Immunol Immunopathol*  *137*, 76-83 | | |
| *Culicoides nubeculosus* | Cul n 2 | Hyaluronidase | | 46.7 |  | | |
|  | Cul n 3 | unknown | | 44.6 |  | | |
|  | Cul n 4 | unknown | | 17.5 |  | | |
|  | Cul n 5 | unknown | | 45.7 | Schaffartzik et al. 2011 | | |
|  | Cul n 6 | unknown | | 16.9 | *Vet Immunol Immunopathol.* | | |
|  | Cul n 7 | unknown | | 20.9 | 139, 200-209. | | |
|  | Cul n 8 | Maltase | | 68.7 |  | | |
|  | Cul n 9 | D7-related | | 15.5 |  | | |
|  | Cul n 10 | unknown | | 47.8 |  | | |
|  | Cul n 11 | Trypsin | | 30.1 |  | | |
|  |  |  | |  |  | | |
| *Culicoides obsoletus* | Cul o 1 | Maltase | | 66.8 |  | | |
|  | Cul o 2 | Hyaluronidase | | 42.3 |  | | |
|  | Cul o 3 | Antigen 5 like | | 27.9 | Van der Meide et al. 2013 | | |
|  | Cul o 4 | Trypsin | | 27.1 | *Vet Immunol Immunopathol.* | | |
|  | Cul o 5 | unknown | | 17.9 | 153, 227-239. | | |
|  | Cul o 6 | D7-related | | 15.2 |  | | |
|  | Cul o 7 | Secreted salivary protein | | 15.0 |  | | |
|  |  |  | |  |  | | |
| *Culicoides obsoletus* | Cul o1P | Kunitz protease inhibitor | | 23.3 | Peeters et al. 2013 | | |
|  | Cul o2P | D7-related | | 17.5 | *Vet J.* 198, 141-147. | | |
|  |  |  | |  |  | | |
| *Culicoides sonorensis* | Cul s 1 | Maltase | | 66.0 | Langner et al. 2009 | | |
|  |  |  | |  | *Int J Parasitol, 39*, 243-250. | | |
| **Fam. Simulidae (blackflies)** | | | | |  | | |
| *Simulium vittatum* | Sim v 1 | Antigen 5 like\* | | 29.8 |  | | |
|  | Sim v 2 | Kunitz protease inhibitor | | 9.6 |  | | |
|  | Sim v 3 | -Amylase | | 28.0 | Schaffartzik et al. 2009 | | |
|  | Sim v 4 | -Amylase | | 26.0 | *Vet Immunol Immunopathol* | | |
|  | SVEP | Et | | 15.3 | 132, 68-77. | | |
|  | SVEP-9 | Erythema protein | | 15.0 |  | | |
|  | SVEP-10 |  | | 15.9 |  | | |

\*cross-reactivity between Cul n 1 and Sim v 1 demonstrated